Open AccessEncouraging long‐term outcomes reported in patients with stage I non‐small cell lung cancer treated with stereotactic ablative radiotherapy
Author(s) -
Barton Mary Kay
Publication year - 2017
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21375
Subject(s) - sabr volatility model , ablative case , medicine , stage (stratigraphy) , radiation therapy , lung cancer , radiosurgery , population , oncology , surgery , volatility (finance) , paleontology , stochastic volatility , environmental health , financial economics , economics , biology
Key Points At a median of 7.2 years of follow‐up, patients with stage I NSCLC who were treated with SABR had outcomes comparable to those noted among patients with stage I disease who were treated with surgery. Research is needed to define whether SABR can be applied to a wider population of patients with NSCLC and how to optimally combine it with systemic therapy.